Fenobam: A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 2, 2005, Pages 711-721

  Porter, Richard H P ^a,d   Jaeschke, Georg ^b   Spooren, Will ^a   Ballard, Theresa M ^a   Büttelmann, Bernd ^b   Kolczewski, Sabine ^b   Peters, Jens Uwe ^b   Prinssen, Eric ^a   Wichmann, Jürgen ^b   Vieira, Eric ^b   Mülemann, Andreas ^a   Gatti, Silvia ^a   Mutel, Vincent ^a,c   Malherbe, Pari ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Chemistry Research   (Switzerland)

^c ADDEX PHARMACEUTICALS   (Switzerland)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2 METHYL 6 PHENYLETHYNYLPYRIDINE; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CALCIUM; DIAZEPAM; FENOBAM; IMIDAZOLE DERIVATIVE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; QUISQUALIC ACID; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CALCIUM METABOLISM; CELL STRAIN HEK293; COMPETITIVE INHIBITION; CONFLICT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EMBRYO; EMOTION; GABAERGIC SYSTEM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPERTHERMIA; IC 50; MALE; MOUSE; NEUROMODULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; STRESS; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; CELL LINE; CELLS, CULTURED; CHO CELLS; CONDITIONING, OPERANT; CONFLICT (PSYCHOLOGY); CRICETINAE; CYCLIC AMP; DNA, COMPLEMENTARY; DRINKING BEHAVIOR; EMOTIONS; FEVER; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; IMIDAZOLES; INOSITOL PHOSPHATES; MALE; MICE; PLASMIDS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; STRESS;

EID: 27144537834     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.089839     Document Type: Article

References (40)

1. Ballard TM, Woolley ML, Prinssen E, Huwyler J, Porter R, and Spooren W (2005) The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology 179:218-229.
2. Brandish PE, Hill LA, Zheng W, and Scolnick EM (2003) Scintillation proximity assay of inositol phosphates in cell extracts: high-throughput measurement of G-protein-coupled receptor activation. Anal Biochem 313:311-318.
3. Breysse N, Baunez C, Spooren W, Gasparini F, and Amalric M (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22:5669-5678.
4. Brodkin J, Busse C, Sukoff SJ, and Varney MA (2002) Anxiolytic-like activity of the mGlu5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol Biochem Behav 73:359-366.
5. Busse CS, Brodkin J, Tattersall D, Anderson JJ, Warren N, Tehrani L, Bristow LJ, Varney MA, and Cosford NDP (2004) The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine MTEP in rodent models of anxiety. Neuropsychopharmacology 29:1971-1979.
6. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
7. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L, Brodkin J, Jiang X, McDonald I, et al. (2003) 3-[(2-Methyl-1,3- thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 46:204-206.
8. Friedmann CTH, Davis LJ, Ciccone PE, and Rubin RT (1980) Phase II double blind controlled study of a new anxiolytic, fenobam (McN-3377) vs placebo. Curr Ther Res 27:144-151.
9. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, et al. (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493-1503.
10. Goldberg ME, Salama AI, Patel JB, and Malick JB (1983) Novel non-benzodiazepine anxiolytics. Neuropharmacology 22:1499-1504.
11. Hunkeler W and Kyburz E (1980) inventors, F. Hoffmann-La Roche, assignee. Urea derivatives. European Patent Application EP 0016371. 1980 Oct 1.
12. Itil TM, Seaman BA, Huque M, Mukhopadhyay S, Blasucci D, Nq KT, and Ciccone PE (1978) The clinical and quantitative EEG effects and plasma levels of fenobam (McN-3377) in subjects with anxiety: an open rising dose tolerance and efficacy study. Curr Ther Res 24:708-724.
13. Kew JN (2004) Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol Ther 104:233-244.
14. Klodzinska A, Chojnacka-Wojcik E, Wieronska J, and Pilc A (2002) Anxiolytic-like effects of MPEP, the selective metabotropic glutamate receptor 5-mGlu5-antagonist, in rats. Pharmacological analysis. Neuropharmacology 43:292.
15. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, and Morikawa K (2000) Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature (Lond) 407:971-977.
16. Lapierre YD and Oyewumi LK (1982) Fenobam: another anxiolytic? Curr Ther Res 31:95-101.
17. Malherbe P, Kew JN, Richards JG, Knoflach F, Kratzeisen C, Zenner MT, Faull RL, Kemp JA, and Mutel V (2002) Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum. Brain Res Mol Brain Res 109:168-178.
18. Malherbe P, Kratochwil N, Zenner MT, Piussi J, Diener C, Kratzeisen C, Fischer C, and Porter RH (2003) Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. Mol Pharmacol 64:823-832.
19. Martin JR, Ballard TM, and Higgins GA (2002) Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav 71:615-625.
20. McGeehan AJ, Janak PH, and Olive MF (2004) Effect of the mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine (MPEP) on the acute locomotor stimulant properties of cocaine, d-amphetamine and the dopamine reuptake inhibitor GBR12909 in mice. Psychopharmacology 15:15.
21. Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prezeau L, Carroll F, Pin JP, et al. (2000) The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b] chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 275:33750-33758.
22. Patel JB, Martin C, and Malick JB (1982) Differential antagonism of the anticonflict effects of typical and atypical anxiolytics. Eur J Pharmacol 86:295-298.
23. Pecknold JC, McClure DJ, and Appeltauer L (1980) Fenobam in anxious outpatients. Curr Ther Res 27:119-123.
24. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, and Allan T (1982) Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 2:129-133.
25. Pilc A, Klodzinska A, Branski P, Nowak G, Palucha A, Szewczyk B, Tatarczynska E, Chojnacka-Wojcik E, and Wieronska JM (2002) Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 43:181-187.
26. Romano C, Sesma MA, McDonald CT, O'Malley K, Van den Pol AN, and Olney JW (1995) Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 355:455-469.
27. Schwarz RD, Dickerson M, Gillespie K, Kinsora J, and Lotarski S (2002) mGluR group I antagonists for the treatment of anxiety. Neuropharmacology 43:308.
28. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, and Mizuno N (1993) Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett 163:53-57.
29. Spooren WP, Gasparini F, Salt TE, and Kuhn R (2001) Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. Trends Pharmacol Sci 22:331-337.
30. Spooren WP, Schoeffter P, Gasparini F, Kuhn R, and Gentsch C (2002) Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur J Pharmacol 435:161-170.
31. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, Porsolt RD, and Gentsch C (2000) Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295:1267-1275.
32. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, and Schoepp DD (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4:131-144.
33. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, Palucha A, Gasparini F, Kuhn R, and Pilc A (2001) Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132:1423-1430.
34. Varney MA, Cosford NDP, Jachec C, Rao SP, Sacaan A, Lin F-F, Bleicher L, Santori EM, Flor PJ, Allgeier H, et al. (1999) SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol Exp Ther 290:170-181.
35. Vaswani M, Linda FK, and Ramesh S (2003) Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27:85-102.
36. Wieronska JM, Smialowska M, Branski P, Gasparini F, Klodzinska A, Szewczyk B, Palucha A, Chojnacka-Wojcik E, and Pilc A (2004) In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling. Neuropsychopharmacology 29:514-521.
37. Wieronska JM, Szewczyk B, Branski P, Palucha A, and Pilc A (2002) Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 23:213-216.
38. Woods JH, Katz JL, and Winger G (1992) Benzodiazepines: use, abuse and consequences. Pharmacol Rev 44:151-347.
39. Wu WN, McKown LA, and O'Neill PJ (1995) In vitro and in vivo metabolism of the antianxiolytic agent fenobam in the rat. J Pharm Sci 84:185-189.
40. Zhu CZ, Wilson SG, Mikusa JP, Wismer CT, Gauvin DM, Lynch IIIJL, Wade CL, Decker MW, and Honore P (2004) Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol 506:107-118.